NovoSeven recombinant Factor VIIa from Novo-Nordisk is now officially a blockbuster. It sold $250M (1450 DKK) in 4Q06, +11% year-over-year in local currencies. The U.S. and Canada comprised half of worldwide sales. (Source: Today’s NVO webcast)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”